For research use only. Not for therapeutic Use.
KDU731（Cat No.:I018295）is a potent inhibitor of diacylglycerol acyltransferase 1 (DGAT1), an enzyme responsible for triglyceride synthesis by catalyzing the final step of triglyceride formation. By inhibiting DGAT1, KDU731 reduces triglyceride accumulation, thereby influencing lipid metabolism. It has applications in the study of metabolic disorders such as obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). KDU731 also plays a role in investigating the relationship between lipid metabolism and various physiological processes, making it a valuable research tool for understanding metabolic regulation and potential therapeutic targets in metabolic diseases.
| Catalog Number | I018295 |
| CAS Number | 1610610-48-4 |
| Molecular Formula | C₂₂H₁₆N₆O₂ |
| Purity | ≥95% |
| Target | Anti-infection |
| Storage | Store at -20°C |
| IUPAC Name | 3-(4-carbamoylphenyl)-N-(5-cyanopyridin-2-yl)-N-methylpyrazolo[1,5-a]pyridine-5-carboxamide |
| InChI | InChI=1S/C22H16N6O2/c1-27(20-7-2-14(11-23)12-25-20)22(30)17-8-9-28-19(10-17)18(13-26-28)15-3-5-16(6-4-15)21(24)29/h2-10,12-13H,1H3,(H2,24,29) |
| InChIKey | YTIYJNWWLQSAAU-UHFFFAOYSA-N |
| SMILES | CN(C1=NC=C(C=C1)C#N)C(=O)C2=CC3=C(C=NN3C=C2)C4=CC=C(C=C4)C(=O)N |
| Reference | [1]. Ward HD, et al. New Tools for Cryptosporidium Lead to New Hope for Cryptosporidiosis. Trends Parasitol. 2017 Sep;33(9):662-664.<br>[2]. Manjunatha UH, et al. A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. Nature. 2017 Jun 15;546(7658):376-380. |
